Regeneron Pharmaceuticals Inc $ 574.06 16.6 (2.98%)
Regeneron Pharmaceuticals Inc News and Headlines -
According to the Historical Data Screen, a new GuruFocus Premium Plus feature, four stocks that have high financial strength and have grown earnings at least 1% every year over the past five years are Check Point Software Technologies Ltd. (CHKP), Grand Canyon Education Inc. (LOPE), MarketAxess Holdings Inc. (MKTX) and Regeneron Pharmaceuticals Inc. (REGN).
New Historical Data Screen feature allows for multiyear data screening
GuruFocus' All-in-One Screener received a new feature where Premium Plus members can screen for stocks for multiple periods at once. Figure 1 illustrates sample Historical Data Screen filters involving
IGM Biosciences, Inc. (IGMS) is one of four health care stocks Jeffries thinks are good buys at the moment, especially for the investor with a higher risk tolerance, according to an article in 24/7 Wall Street.
Given the boost the stock has enjoyed since the brokerage's report came out on Sept.15, shares of the Mountain View, California-based biotech might seem better suited for investors who also have a long-term horizon.
IGM's stock price is up 375% since the company went public a little more than a year ago. It has traded as high as $90 during the past
Investors reacted favorably to the announcement that Chinese biopharmaceutical company Innovent Biologics Inc. (HKSE:01801) and Eli Lilly and Co. (LLY) have expanded their licensing agreement for a cancer drug.
The deal gives Indianapolis-based Eli Lilly the rights to the Tyvyt, which the two have been selling in China for a form of lymphoma. Biopharma Dive reoported Eli Lilly and Innovent had already split rights to the drug based on a 2015 agreement. They'll continue to share the profits under the new deal, but Eli Lilly now obtains rights to Tyvyt everywhere outside of China. Innovent received $200 million upfront from
Managed by Jean Hynes, the fund invests in a variety of health care-related stocks from around the world in order to achieve long-term capital appreciation. She picks stocks of companies that have high-quality balance sheets, strong management teams and the potential for new products that will generate consistently above-average revenue and earnings growth.
Based on these criteria, the fund established holdings in Stryker Corp. (SYK), Royalty Pharma PLC (RPRX) and WuXi Biologics (Cayman) Inc. (HKSE:02269) during
In light of Novavax Inc. (NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital. The top five stocks according to the Joel Greenblatt Magic Formula Screen, a Premium value screen, are Alexion Pharmaceuticals Inc. (ALXN), Novo Nordisk A/S (NVO), Galapagos NV (GLPG), Regeneron Pharmaceuticals Inc. (REGN) and Vertex Pharmaceuticals Inc. (VRTX).
Novavax continues big surge on coronavirus vaccine federal aid
Shares of the Gaithersburg, Maryland-based company closed at $104.56, close to a 52-week high of
Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route. Rumor has it that the French pharmaceutical giant has its eyes on San Rafael, California-based Biomarin Pharmaceutical Inc. (BMRN).
Speculation heated up after Sanofi announced it was selling about $11 billion worth of shares it owns in Regeneron Pharmaceuticals Inc. (REGN). That would be a nice down payment, but Sanofi will have to dig deeper into its pockets because Biomarin has a market value of nearly $22 billion. Year to date, its shares are
The Nasdaq Composite Index closed on Wednesday above 10,000 for the first time in history as investors continue their optimistic bet on the economy recovering from the coronavirus-related shutdown. Among the S&P 500 companies trading on the Nasdaq exchange, the five stocks with the largest year-to-date total return are DexCom Inc. (DXCM), Regeneron Pharmaceuticals Inc. (REGN), Nvidia Corp. (NVDA), PayPal Holdings Inc. (PYPL) and Abiomed Inc. (ABMD).
Tech-heavy Nasdaq reaches five-digit intraday high, boosted by Apple and Amazon
Sanofi’s (SNY) decision to hedge its bet on developing a vaccine for Covid-19 has helped nearly double the year-to-date share price of a Boston-area therapeutics company.
Translate Bio Inc.’s (TBIO) partnership with Sanofi builds on the three-year pact the companies signed in June 2018 to use Translate’s technology called mRNA to develop vaccines for up to five infectious diseases. Given the worldwide pandemic, the Covid-19 vaccine is now front and center.
GENE News reported that Translate Bio CEO Ronald C. Renaud Jr. said the companies hope to begin animal testing in weeks. “We have a goal to be in the
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs.
General Mills Inc. reached the 52-week high of $60.67
General Mills (GIS) is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food and ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, Blue Buffalo and Haagen-Dazs.
The price of General Mills Inc. shares has reached $60.67, which is 0.4% off the 52-week high of $60.92. General Mills Inc. has a
As [url=https://www.gurufocus.com/StockBuy.php?GuruName=David+Herro]David Herro[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=David+Herro]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=David+Herro]Portfolio[/url]) wrote in his lead letter, it was a difficult quarter for global markets and the Oakmark Global Select Fund was not exempt. The Fund declined 30.7% for the quarter ended March 31, compared to the MSCI World ex U.S. Index, which lost 21.1%. Since the Fund’s inception in October 2006, it has returned an average of 4.8% per year. The top contributor for both the quarter and the past six months was Regeneron Pharmaceuticals (REGN) (U.S.), while the largest detractor for the same time periods was CNH Industrial (CNHI) (U.K.).
While we are disappointed
Our top contributor in the quarter and over the past six months was Regeneron Pharmaceuticals (REGN). The company is at the forefront of developing potential coronavirus treatments. The relative attractiveness of Regeneron stock has diminished substantially given its strong outperformance, but we still believe the company is selling at a discount to our estimate of its intrinsic value.
From [url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Bill Nygren[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Bill+Nygren]Portfolio[/url])'s Oakmark Select Fund first-quarter 2020 shareholder commentary.
The Oakmark Select Fund was down 33% for the quarter, trailing the S&P 500 Index’s negative 20% return, in a quarter in which the Russell 1000 Value Index underperformed the Russell 1000 Growth Index by 13%. As [url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Bill Nygren[/url] ([url=https://www.gurufocus.com/StockBuy.php?GuruName=Bill+Nygren]Trades[/url], [url=https://www.gurufocus.com/holdings.php?GuruName=Bill+Nygren]Portfolio[/url]) pointed out in his quarterly commentary, what started out as a relatively benign quarter turned terrible from late February onwards.
Our top contributor in the quarter and over the past six months was Regeneron Pharmaceuticals (REGN). The company is at the forefront of developing potential coronavirus treatments. The relative attractiveness of Regeneron stock has diminished substantially given its
Market volatility spiked during the first quarter of 2020 due to the considerable economic and social impact from the coronavirus. The Oakmark Fund declined 30% during the quarter, trailing the 20% decline for the S&P 500. Significant market volatility pushed share prices well below our estimates of intrinsic value and, therefore, we believe our portfolio is more attractively valued today than it was before the downturn. This has given us the opportunity to rebalance the portfolio toward companies with higher risk-adjusted returns, largely by trimming shares of our holdings that withstood the downturn relatively well. In one example of this
When the first quarter of 2020 ended on March 31, the S&P 500 was down 20% year to date on the back of the fear caused by the novel coronavirus outbreak as well as the oil price war between OPEC leader Saudi Arabia and Russia. Over the same period, the Nasdaq Composite declined 14.2% and the Dow Jones Industrial Average posted a return of 23.2%.
Some of the companies within the S&P 500 Index, however, had better luck. According to the GuruFocus All-in-One Screener, a feature for Premium users, stocks that beat the benchmark
The patient, the U.S. economy, is sick and remains in a coma. Although the patient was never healthier six weeks ago, now the economy has fallen victim to a worldwide pandemic that has knocked the global economy on its back. On the surface, the physical impact of coronavirus on the health of the 330 million Americans seems relatively modest statistically (4,394 deaths vs. 45,000 estimated common flu deaths this season). However, in order to kill this insidious novel coronavirus, which has spread like wildfire across 200 countries, governments have been forced to induce the economy into a coma, by closing
In the past month, the pharmaceutical index has declined about half as much as the Dow Jones Industrial Average and the S&P 500. That’s logical considering science-based companies are those entities governments and the public are relying on to produce tests to detect the Covid-19 virus and, hopefully, develop a vaccine and a treatment.
Shares of one of the larger-cap companies, Regeneron (RGEN), are up about 25% in the past 30 days. The Tarrytown, New York-based company has had a relationship since 2014 with the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). In early
According to GuruFocus Insider Data, the recent CFO sells were for Regeneron Pharmaceuticals Inc. (REGN), Zoetis Inc. (ZTS) and Zoom Video Communications Inc. (ZM).
Regeneron Pharmaceuticals Inc. Executive Vice President Finance CFO Robert E. Landry sold 414 shares
Executive Vice President Finance CFO Robert E. Landry sold 414 shares for $452.49 per share on Feb. 26. Since then, the stock price has increased by 2.89%.
Regeneron Pharmaceuticals Inc. has a market cap of $51.22 billion and its shares were traded around $465.55. The company has a price-earnings ratio of 25.22 and price-sales ratio of 6.77. Over the past five years,
According to GuruFocus, these stocks have reached their 52-Week Highs.
Twenty-First Century Fox Inc. reached the 52-week high of $41.70
21st Century Fox (FOXAV) is a media conglomerate with a wide range of assets, including a film studio, broadcast television, cable networks and direct-broadcast satellite TV.
The price of Twenty-First Century Fox Inc. shares has reached $41.70, which is 0.6% off the 52-week high of $41.95. Twenty-first Century Fox Inc. has a market cap of $96.15 billion; its shares were traded around $41.70 with a price-earnings ratio of 6.67 and a price-sales ratio of
According to GuruFocus insider data, the recent chief financial officer sells included Chipotle Mexican Grill Inc. (CMG), Tesla Inc. (TSLA) and Regeneron Pharmaceuticals Inc. (REGN).
Chipotle Mexican Grill CFO sold 4,063 shares
CFO Jack Hartung sold 4,063 shares for $915.03 per share on Feb. 14. Since then, the stock has declined 15.97%. Chipotle Mexican Grill has a market cap of $21.35 billion and its shares were traded around $768.93. The company has a price-earnings ratio of 62.16 and a price-sales ratio of 3.90. Over the past 10 years, the restaurant chain had an annual average earnings growth of 6.90%.
The U.S. stock indices are filled with small pharma and biotech stocks that are purely research-oriented. Most of these companies don’t even have revenues and are entirely focused on building a strong pipeline of drugs and vaccines to counter various diseases that are affecting mankind.
The problem with these companies is that their low or nonexistent revenues result in a weak investor perception as the qualitative benefits of their research cannot be measured tangibly. However, with the outbreak of the Wuhan coronavirus, the importance of investing in the research of such companies is suddenly a hot topic in the investor